Legend Biotech Reports Fourth Quarter and Full Year 2023 Res

SOMERSET, N.J.--(BUSINESS WIRE)--Mar 11, 2024--

Related Keywords

Austria , United States , Germany , New Jersey , Belgium , American , Birk Vanderwee , Ying Huang , Jessie Yeung , Alexandra Ventura , Drug Administration , Oncologic Drugs Advisory Committee , Global Development Plan , Committee For Medicinal Products Human Use , Development Expenses , Janssen Biotech Inc , Exchange Commission , Twitter , Johnson , Probio Biotech Co Ltd , American Society Of Hematology Annual Meeting , Legend Biotech Corporation , Linkedin , Biotech Corporation , Legend Biotech , Chief Executive Officer , Medicinal Products , Human Use , Novartis Pharma , Delta Like Ligand , Senior Vice President , Global Manufacturing , General Manager , Supply Chain , Hematology Annual Meeting , Janssen Biotech , Janssen Agreement , Year Ended December , Cash Equivalents , Time Deposits , Investigational New Drug , Conference Call Details , Private Securities Litigation Reform Act , Annual Report , Months Ended December , Ended December , Reported Outcomes , Ciltacabtagene Autoleucel Vs Standard , Lenalidomide Refractory Multiple Myeloma , Hematology Annual , Business Wire , Region ,